Rituximab utilization for approved and off‐label nononcology indications and patients' experiences with the Patient Alert Card

• Päätekijät: Khaled Sarsour (Tekijä), Senam Beckley‐Kartey (Tekijä), Simone Melega (Tekijä), Adefowope Odueyungbo (Tekijä), Petra Kirchner (Tekijä), Natasha Khalife (Tekijä), Joanne Bangs (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Wiley, 2020-02-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract This study used retrospective chart review and survey data to evaluate: (1) off‐label use of rituximab (MabThera®/Rituxan®) in autoimmune conditions and (2) patients' receipt and knowledge of the Patient Alert Card (PAC), a risk minimization measure for progressive multifocal leukoence...